The Galleri multi-cancer detection test made headlines when its landmark NHS trial failed to meet its primary endpoint, sending Grail's stock down nearly 50%. But does that mean Galleri is useless? Not exactly. In this episode, Dr. Matt Kaeberlein breaks down what the NHS Galleri trial actually measured, why missing a primary endpoint doesn't tell the whole story, and what the results mean for three distinct groups: the general population, high-risk individuals, and people considering the test for themselves.